Events

DGE’s 4th Virtual Clinical Trials Conference

Monday, May 17, 2021

On Monday, May 17th, 2021, pharma companies, medical vendors, and clinicians are invited to attend the 4th Virtual Clinical Trials conference – the industry’s leading, longest-lasting conference on virtual clinical trials. The event is hosted by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. 

On May 17-18th The 4th Virtual Clinical Trials will increase your ability to execute your decentralized trial, reduce site visits, accelerate timelines and gather data faster.  Hear from top industry experts that will give you the tools to implement remote trials and reduce workloads for clinical trial sites at an accelerated rate.

The 2-day event will feature speeches, keynotes, and discussions from over 25 speakers on the increasing needs, benefits, and potential of virtual clinical trials. The 4th Virtual Clinical Trials Conference offers this unique opportunity to sponsors, and pharma companies to understand the potential of virtual clinical trials and how to remove roadblocks and barriers for collecting and utilizing patient data.

The event will commence with an introductory speech by Craig Lipset, founder of Clinical Innovation Partners. Craig Lipset is a visionary leading the forefront of innovations in clinical research and medicine development.

Influential Opinion Leaders who will present will include:

  • Angel Soubhie, BAYER, HEAD CLINICAL TRIAL SCIENTISTS – MEDICAL DIRECTOR
  • Jeremy Price, PFIZER, DIRECTOR, CLINICAL OPERATIONS STRATEGIC PARTNERSHIPS
  • Antonieta Sosa, JANSEEN, DIRECTOR, CLINICAL INNOVATION
  • Stephen Lutsch, LEO PHARMA, DIRECTOR, HEAD OF REVOLUTIONIZE CLINICAL TRIALS
  • Maimah Karmo, TIGERLILY FOUNDATION, CEO, PATIENT ADVOCATE

Clinicians, trial managers, clinical data experts, vendors, pharma companies, and scientists should leverage the opportunity offered by the event, as it is will showcase:

  • A roadmap for turning urgent responses to COVID into permanent new processes that will keep your momentum going
  • Best practice on updating SOPs for these unprecedented problems
  • Strategies to maintain patient centricity, safety, and feedback throughout the trial
  • An up-to-date review of new assessments and expectations from regulators
  • Key techniques for collaborating around new data standards with service providers

COVID-19 has increased the need for virtual clinical trials. The key theme and the objective of the conference is to discuss and discover the innovation, recruitment, and application of virtual clinical trials to a wider pharma sector while keeping the patient experience in mind.

For tickets to the event, please visit https://ibn.fm/QduhD

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

The global market for brain tumor treatments is experiencing significant transformation powered by advances in…

1 day ago

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

A team of researchers has developed a “cost-effective” and simple blood test with the potential…

3 days ago

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…

3 days ago

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…

4 days ago

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…

1 week ago

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…

1 week ago